Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Year: 2018
Type: conference-abstract
Source: Blood
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Instituto de Investigación Biomédica de Salamanca, Amsterdam UMC Location Vrije Universiteit Amsterdam, Emory University, Winship Cancer Institute, Centre Hospitalier Universitaire de Nantes, Nantes Université, Institut Català d'Oncologia, University of Southern Denmark, Vejle Sygehus, Centre Hospitalier Universitaire de Tours, Karolinska University Hospital, Karolinska Institutet, Janssen Research & Development (United States), Janssen (Belgium), Janssen (United Kingdom), Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2903287123